Technical Analysis for RANI - Rani Therapeutics Holdings, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bullish Signal Line Cross | Bullish | -1.88% | |
| Wide Bands | Range Expansion | -1.88% | |
| Pocket Pivot | Bullish Swing Setup | -3.17% | |
| Wide Bands | Range Expansion | -3.17% | |
| Pocket Pivot | Bullish Swing Setup | 2.38% | |
| Volume Surge | Other | 2.38% | |
| Wide Bands | Range Expansion | 2.38% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 14.91% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 14.91% | |
| Narrow Range Bar | Range Contraction | 14.91% |
| Alert | Time |
|---|---|
| Gap Up Closed | about 2 hours ago |
| Gap Up Partially Closed | about 2 hours ago |
| Reversed from Up | about 2 hours ago |
| Gapped Up (Partial) | about 2 hours ago |
| Down 5% | about 2 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/08/2024
Rani Therapeutics Holdings, Inc. Description
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-103, a glucagon-like peptide-1 mimetic to treat type 2 diabetes; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was founded in 2012 and is headquartered in San Jose, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Diabetes Endocrine System Osteoporosis Peptide Hormones Growth Hormone Psoriatic Arthritis Glands Growth Hormone Deficiency Neuroendocrine Tumors Acromegaly Glucagon Hypoparathyroidism Neuroendocrinology Parathyroid Hormone
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.75 |
| 52 Week Low | 1.82 |
| Average Volume | 165,281 |
| 200-Day Moving Average | 3.45 |
| 50-Day Moving Average | 4.66 |
| 20-Day Moving Average | 6.46 |
| 10-Day Moving Average | 6.82 |
| Average True Range | 0.70 |
| RSI (14) | 67.00 |
| ADX | 36.97 |
| +DI | 35.42 |
| -DI | 14.38 |
| Chandelier Exit (Long, 3 ATRs) | 6.65 |
| Chandelier Exit (Short, 3 ATRs) | 5.62 |
| Upper Bollinger Bands | 8.29 |
| Lower Bollinger Band | 4.63 |
| Percent B (%b) | 0.77 |
| BandWidth | 56.59 |
| MACD Line | 0.76 |
| MACD Signal Line | 0.76 |
| MACD Histogram | 0.0011 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.53 | ||||
| Resistance 3 (R3) | 8.55 | 8.22 | 8.35 | ||
| Resistance 2 (R2) | 8.22 | 7.94 | 8.21 | 8.29 | |
| Resistance 1 (R1) | 7.84 | 7.77 | 7.67 | 7.82 | 8.23 |
| Pivot Point | 7.50 | 7.50 | 7.42 | 7.49 | 7.50 |
| Support 1 (S1) | 7.12 | 7.23 | 6.96 | 7.10 | 6.69 |
| Support 2 (S2) | 6.79 | 7.06 | 6.78 | 6.63 | |
| Support 3 (S3) | 6.41 | 6.79 | 6.57 | ||
| Support 4 (S4) | 6.39 |
